1043-3155 Pediatr Neurol Briefs pedneurbriefs Pediatr Neurol Briefs Pediatric Neurology Briefs Pediatr Neurol Briefs 2166-6482 1043-3155 2166-3155 Pediatric Neurology Briefs Publishers Chicago, IL, USA PNB-1-38 10.15844/pedneurbriefs-1-5-11 Language and Behavior Neurology Pediatrics Nervous System Diseases Child Development Brain Diseases Neurosurgery Child Infant Methylphenidate and Attention Deficit Disorder http://orcid.org/0000-0002-0173-7931 Millichap J. Gordon MD 1 2 * Division of Neurology, Children's Memorial Hospital, Chicago, IL Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL Correspondence: Dr. J. Gordon Millichap, E-mail: jgmillichap@northwestern.edu 10 1987 01 08 2016 1 5 38 38 Copyright: © 1987 The Author(s) 1987 This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder

The relative effects of sustained release (Ritalin [SR-207[) and standard methylphenidate (Ritalin 10 mg, BD) on cognitive and social behavior in 22 boys with ADD were investigated at a summer treatment program supervised by the Western Psychiatric Institute, Univ of Pittsburgh School of Medicine, PA.

 Standard Methylphenidate Slow-Release Dextroamphetamine Sustained-Release Preparation

The relative effects of sustained release (Ritalin [SR-207[) and standard methylphenidate (Ritalin 10 mg, BD) on cognitive and social behavior in 22 boys with ADD were investigated at a summer treatment program supervised by the Western Psychiatric Institute, Univ of Pittsburgh School of Medicine, PA. Group analyses of data showed that both drugs were effective but standard methylphenidate was superior to SR-20 on measures of disruptive behavior and SR-20 had a slower onset on a continuous performance task. Analyses of individual responsivity showed that most boys responded more positively to the standard compared to the sustained-release preparation of methylphenidate. The authors note that in contrast to advertising material, the effects of SR-20 and standard methylphenidate are not equivalent. They recommend pemoline or slow-release dextroamphetamine in preference to SR-20 if a single daily dose sustained effect is required. [1]

COMMENT: Stimulant medications used in the treatment of ADDH have different half lives: methylphenidate 2.6 hours on a dose of 0.60 mg/kg; dextroamphetamine 6.8 hours with 0.45 mg/kg; and pemoline 8.36 hours after doses up to 110 mg (see Zametkin AJ, Rapoport JL in Ped Neur Briefs 1987:1 (5):37). Clinical responses, however, are not always correlated with the half life of the drug or with plasma levels which may vary considerably from day to day in patients with a fixed dose. Previous studies have shown that time release Dexedrine may not act for longer time periods than the standard tablet form. These inconsistencies, together with the findings in the present study, suggest that standard methylphenidate or pemoline remain the treatments of choice in ADDH.

 Pelham WE Jr Sturges J Hoza J Schmidt C Bijlsma JJ Milich R Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder Pediatrics 1987 Oct 80 4 491 501 3658567